Mesoblast Ltd MESO.OQ, MESO.O is expected to report resultson February 27 for the period ending September 30 2024
The Melbourne Victoria-based company is expected to report revenue of $1.493 million, according to the estimate from one analyst, based on LSEG data.
LSEG's mean analyst estimate for Mesoblast Ltd is for a loss of 14 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Mesoblast Ltd is $27.00, above its last closing price of $16.23.
This summary was machine generated February 25 at 11:12 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)